BR112019025578A2 - Mesembrenol e/ou mesembranol para profilaxia e tratamento de pacientes que sofrem de epilepsia e doenças associadas - Google Patents

Mesembrenol e/ou mesembranol para profilaxia e tratamento de pacientes que sofrem de epilepsia e doenças associadas

Info

Publication number
BR112019025578A2
BR112019025578A2 BR112019025578-8A BR112019025578A BR112019025578A2 BR 112019025578 A2 BR112019025578 A2 BR 112019025578A2 BR 112019025578 A BR112019025578 A BR 112019025578A BR 112019025578 A2 BR112019025578 A2 BR 112019025578A2
Authority
BR
Brazil
Prior art keywords
treatment
prophylaxis
mesembrenol
mesembranol
epilepsy
Prior art date
Application number
BR112019025578-8A
Other languages
English (en)
Inventor
Dimpfel Wilfried
Original Assignee
Hg&H Pharmaceuticals (Pty) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hg&H Pharmaceuticals (Pty) Ltd filed Critical Hg&H Pharmaceuticals (Pty) Ltd
Publication of BR112019025578A2 publication Critical patent/BR112019025578A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

a invenção refere-se aos alcaloides mesembranol ou mesembrenol ou sais farmaceuticamente aceitáveis ou complexos dos mesmos, para uso na profilaxia ou no tratamento de uma doença que responde ao tratamento com um antagonista de receptor do ampa (ácido a-amino-3-hidróxi-5-metil-4-isoxazolpropiônico). a profilaxia ou o tratamento atenua a neurotransmissão mediada por ampa no hipocampo de um indivíduo.
BR112019025578-8A 2017-07-26 2018-07-25 Mesembrenol e/ou mesembranol para profilaxia e tratamento de pacientes que sofrem de epilepsia e doenças associadas BR112019025578A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA201705072 2017-07-26
ZA2017/05072 2017-07-26
PCT/IB2018/055535 WO2019021196A1 (en) 2017-07-26 2018-07-25 MESEMBRENOL AND / OR MESEMBRANOL FOR THE PROPHYLAXIS AND TREATMENT OF PATIENTS SUFFERING FROM EPILEPSY AND RELATED DISEASES

Publications (1)

Publication Number Publication Date
BR112019025578A2 true BR112019025578A2 (pt) 2020-06-16

Family

ID=63312208

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019025578-8A BR112019025578A2 (pt) 2017-07-26 2018-07-25 Mesembrenol e/ou mesembranol para profilaxia e tratamento de pacientes que sofrem de epilepsia e doenças associadas

Country Status (7)

Country Link
US (1) US20200215033A1 (pt)
EP (1) EP3658167A1 (pt)
JP (1) JP7217259B2 (pt)
AU (1) AU2018307730B9 (pt)
BR (1) BR112019025578A2 (pt)
CA (1) CA3064164A1 (pt)
WO (1) WO2019021196A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11999694B2 (en) 2021-10-29 2024-06-04 Sensorium Therapeutics, Inc. Delivery of therapeutic alkaloid compounds
WO2023166304A1 (en) * 2022-03-02 2023-09-07 Kanna Health Ltd Compounds for the use in the treatment of mood disorders
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA974576B (en) 1996-06-04 1998-02-04 Farmarc Nederland Bv Pharmaceutical composition.
US8258154B2 (en) 2006-07-07 2012-09-04 Kalypsys Inc. Bicyclic heteroaryl inhibitors of PDE4
WO2010106495A1 (en) * 2009-03-20 2010-09-23 H.L. Hall & Sons Limited Sceletium extract and uses thereof
ES2759675T3 (es) 2009-03-20 2020-05-11 Hg&H Pharmaceuticals Pty Ltd Uso de composiciones farmacéuticas que contienen mesembrenona
BR112018008006A2 (pt) 2015-11-13 2018-10-30 Eisai R&D Management Co., Ltd. composto de piranodipiridina

Also Published As

Publication number Publication date
JP2020528436A (ja) 2020-09-24
WO2019021196A1 (en) 2019-01-31
AU2018307730B2 (en) 2024-01-25
US20200215033A1 (en) 2020-07-09
AU2018307730B9 (en) 2024-02-15
EP3658167A1 (en) 2020-06-03
JP7217259B2 (ja) 2023-02-02
WO2019021196A9 (en) 2019-05-23
AU2018307730A1 (en) 2020-01-02
CA3064164A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112015027682A2 (pt) Uso de sobetirome no tratamento de doenças ou condições associadas com a desmielinização ou mielinização insuficiente
BR112019010646A2 (pt) métodos de tratamento de condições inflamatórias
BR112013027554A2 (pt) "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
BR112017008093A2 (pt) processos para tratamento de doenças oculares
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
BR112012001297A2 (pt) conector.
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
BR112019025578A2 (pt) Mesembrenol e/ou mesembranol para profilaxia e tratamento de pacientes que sofrem de epilepsia e doenças associadas
BR112017027843A2 (pt) formulações farmacêuticas compreendendo tenofovir e emtricitabina
BR112019006463A2 (pt) composição oral de canabinoides extraídos e métodos de uso da mesma
BR112017028140A2 (pt) formulações farmacêuticas
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112021018262A2 (pt) Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
BR112015012497A2 (pt) combinações farmacêuticas

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.